Lilly explicitly cited this in their TRIUMPH-4 reporting
calculated the risk to be 4.8/10,000 in groups taking GLP-1 RAs compared to 4.6/10,000 in the control groups, failing to show a statistically significant difference in aspiration or other complications between the two groups (Chang et al
The UK and Europe may not reach the level of the US, but even 2% to 4% penetration in key adult demographics would drive substantial category change, says Patrick Young, managing director of PRS IN VIVO, a global market and behavioural science research consultancy
But the big question is how well its growth will hold up in the future, as other GLP-1 drugs inevitably enter the market
The market is further safeguarded by a dense patent landscape surrounding these devices
The control group, in contrast, followed a traditional diet with three meals (breakfast, supper, dinner) per day and two snacks